PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Clinical trial finds concurrent therapy not necessary to achieve high pathological in breast cancer

Phase III trial examines pathological complete response rate

2013-11-13
(Press-News.org) Contact information: William Fitzgerald
wbfitzgerald@mdanderson.org
713-792-9518
University of Texas M. D. Anderson Cancer Center
Clinical trial finds concurrent therapy not necessary to achieve high pathological in breast cancer Phase III trial examines pathological complete response rate HOUSTON — Giving trastuzumab and anthracyclines at the same time is effective at treating HER-2-positive breast cancer, but there is concern that this combination can be associated with an increased risk of cardiac toxicity. New research from Aman Buzdar M.D., professor and vice president of clinical research at The University of Texas MD Anderson Cancer Center, and colleagues in the Alliance for Clinical Trials in Oncology, shows these agents do not need to be given concurrently to achieve a high rate of complete pathological remission.

The findings, published in the journal Lancet Oncology, investigated the timing of trastuzumab administration with anthracycline and taxane chemotherapy.

"In a previous MD Anderson study concurrent administration of trastuzumab with chemotherapy, including anthracyclines, demonstrated high pathologic complete response rates in breast cancer patients with HER-2-positive disease," Buzdar said. "In the current trial, we examined whether concurrent administration of anthracyclines with trastuzumab was necessary to achieve the high pathologic response rates or whether these drugs could be given sequentially. Findings show that high pathologic response rates were observed in both treatment groups with similar cardiac safety profiles in both arms of the trial."

The randomized phase III trial enrolled 280 women with operable HER-2 positive invasive breast cancer at 36 centers across the United States from September 2007 through December 2011.

Patients were randomly assigned to two treatment regimens, 138 in the sequential group who received fluorouracil, epirubicin and cyclophosphamide on day one of a 21-day cycle for four cycles followed by paclitaxel plus trastuzumab weekly for 12 weeks.

The 142 patients in the concurrent group were treated with paclitaxel and trastuzumab weekly for 12 weeks. This was followed by fluorouracil, epirubicin and cyclophosphamide on day one of a 21-day cycle with trastuzumab on days one, eight and 15 of the 21-day cycle for four cycles. Each patient in both arms of the trial received a total of one year of trastuzumab therapy. The primary endpoint of the trial was the proportion of patients who had pathological complete remission in the breast, defined as the percentage of women who started the neoadjuvant treatment with no histological evidence of disease in the breast at surgery.

"If a patient achieves complete pathological remission, we know from previous experience that more than 90 percent continue to remain free of their disease at longer follow-up," Buzdar said, who also served as the principal investigator of the trial.

Similar responses seen in both treatment groups

The findings showed that 56.5 percent of patients in the sequential group had a complete pathological remission versus 54.2 percent of the patients who received the concurrent regimen, a difference that was not significant.

Next Steps

Researchers are now in the process of analyzing the genomic profiles of the breast tumors that were obtained during the trial to better understand patient responses. The purpose is to evaluate the specific characteristics of a tumor that is sensitive to these therapies, as well as identify the profiles that are resistant.

Kelly Hunt, M.D., professor in MD Anderson's Department of Surgical Oncology and co-principle investigator of the trial, said if we can identify the patients most likely to have pathologic complete response with therapy, we can reduce or potentially eliminate surgery for these patients in the future.

### This research was supported by the National Cancer Institute grant U10 CA76001 to the American College of Surgeons Oncology Group and the National Cancer Institute to the Alliance for Clinical Trials in Oncology CA33601.

In addition to Buzdar, other MD Anderson authors include: Kelly Hunt, M.D., Funda Meric-Bernstam, M.D., and Michael Ewer, M.D. Other authors include: Marilyn Leitch, M.D., The University of Texas Southwestern Medical Center, Matthew Ellis, Ph.D., Washington University School of Medicine in St. Louis, Judy Boughey, M.D., The Mayo Clinic, Gary Unzeitig, M.D., Doctors Hospital of Laredo Texas, Melanie Royce, M.D., Ph.D., University of New Mexico Cancer Center and Linda McCall, Duke Cancer Institute. The Alliance for Clinical Trials in Oncology is a clinical trials network sponsored by the National Cancer Institute that consists of nearly 10,000 cancer specialists at hospitals, medical centers and community clinics across the country and Canada. The Alliance is dedicated to developing and conducting clinical trials with promising new cancer therapies and utilizes the best science to develop optimal treatment and prevention strategies for cancer, as well as researching methods to alleviate side effects of cancer and cancer treatments.


ELSE PRESS RELEASES FROM THIS DATE:

Parental monitoring lowers odds of a gambling problem

2013-11-13
Parental monitoring lowers odds of a gambling problem Parental supervision at ages 11-14 lowers risk for problem gambling by age 22 November 12, 2013—Keeping an eye on your child can lower their odds for gambling by young adulthood, ...

Bring a 50,000-degree plasma into your living room

2013-11-13
Bring a 50,000-degree plasma into your living room An online open-user experiment puts users in control of a real physics laboratory With the rise of online open course platforms such as Khan Academy, MIT OpenCourseWare and iTunes U, it has never been easier to ...

NASA sees Veteran's Day solar flare

2013-11-13
NASA sees Veteran's Day solar flare The sun emitted a significant solar flare that peaked at 12:14 a.m. EST on Nov. 10, 2013. Solar flares are powerful bursts of radiation. Harmful radiation from a flare cannot pass through Earth's atmosphere ...

Structure of bacterial nanowire protein hints at secrets of conduction

2013-11-13
Structure of bacterial nanowire protein hints at secrets of conduction Electrically conducting bacteria important for energy, environment and technology RICHLAND, Wash. -- Tiny electrical wires protrude from some bacteria and contribute to ...

Riding an electron wave into the future of microchip fabrication

2013-11-13
Riding an electron wave into the future of microchip fabrication Computer simulation explores how intense plasma waves generate suprathermal electrons, which are critical to microchip fabrication Advanced plasma-based etching is a key enabler of Moore's Law that ...

Putting a new spin on tokamak disruptions

2013-11-13
Putting a new spin on tokamak disruptions Rapid plasma rotation may be the key to softening the blow of powerful plasma disruptions In the quest for fusion energy on earth, researchers use magnetic fields to insulate hot plasma from the walls of the chamber to ...

Researcher finds potential new use for old drugs

2013-11-13
Researcher finds potential new use for old drugs From malaria to cancers and immune-related diseases PULLMAN, Wash. – A class of drugs used to treat parasitic infections such as malaria may also be useful in treating cancers and immune-related diseases, a new WSU-led ...

Our relationship with food: What drives us to eat and new insights into eating disorders

2013-11-13
Our relationship with food: What drives us to eat and new insights into eating disorders New treatments for binge eating, how our diet impacts brain function, and the connection between marijuana and obesity SAN DIEGO — A growing body of evidence shows the impact of ...

Stepparents are not always evil

2013-11-13
Stepparents are not always evil Parents' strategy to love their children depends on more than blood ties Contrary to common belief, parents do not generally treat their stepchildren less favourably than their own. Until now, many researchers believed ...

No hot flashes? Then don't count on hormones to improve quality of life

2013-11-13
No hot flashes? Then don't count on hormones to improve quality of life CLEVELAND, Ohio (November 13, 2013)—Hormones at menopause can help with sleep, memory, and more, but only when a woman also has hot flashes, find researchers ...

LAST 30 PRESS RELEASES:

Digestive cancers in China: A two-decade burden with uneven gains in life expectancy

ANXA2+ migratory hepatocytes identified as key players in human liver regeneration

Researchers demonstrate a new material to reduce power consumption of electronics

New chemical tool may improve development of key drug components

IEEE study achieves efficient integration of quantum dot lasers on silicon chiplets

Researchers discover that sound stress alone can prolong and intensify pain

Less pain, more gain: A new recipe for safer, stronger mRNA vaccines

Surprising finding could pave way for universal cancer vaccine

Gene essential for vitamin D absorption could help unlock treatments for cancer and autoimmune diseases

Don’t feed the animals: Researchers warn of risks tied to wildlife interactions

New layered compound promotes two-dimensional magnetism researches and room-temperature magnetic applications

From passive to intelligent: Bioengineered organs meet electronics

Cassava witches’ broom disease takes flight in South America

Recycled tyre tech boosts railway resilience and cuts waste

From kelp to whales: marine heatwaves are reshaping ocean life

Short-term digital mental health interventions reduces depression and anxiety in Ukrainian children and adolescents displaced by war

Guselkumab demonstrates superior efficacy in landmark clinical trials and offers new hope to Crohn’s disease patients

Here’s how the U.S. military can trim its massive carbon footprint

What is chronic venous insufficiency?

Gene editing offers transformative solution to saving endangered species

Scar tissue in athletes’ hearts tied to higher risk of dangerous cardiac rhythms

Cracking the code of force-driven chemistry

What ever-growing incisors can teach us about genetic disease

UCalgary led research helps kids with acute gastroenteritis recover at home

“Sisters together’: Antiracist activism and the fight for trans inclusion at the Michigan Womyn’s Music Festival

A new pathway helps clean up toxic chemicals from plant cells

WPI researchers develop cleaner, scalable process to recycle lithium-ion batteries

NASA to launch SNIFS, Sun’s next trailblazing spectator

Programmable DNA moiré superlattices: expanding the material design space at the nanoscale

Polymer coating extends half life of MXene-based air quality sensor by 200% and enables regeneration

[Press-News.org] Clinical trial finds concurrent therapy not necessary to achieve high pathological in breast cancer
Phase III trial examines pathological complete response rate